postinfected bronchiolitis obliterans
Conditions
Interventions
control group:conventional treatment
experimental group:conventional treatment combined with oral low dose azithromycin
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1.6 months to 18 years old, regardless of gender; 2.The diagnosis criteria of BO refer to Expert Consensus on Diagnosis and Treatment of Bronchiolitis Obliterans in Children (2023) formulated by Respiratory Group of Pediatrics Branch of Chinese Medical Association, and the diagnosis criteria of severe pneumonia refer to Norms for Diagnosis and Treatment of Community-Acquired Pneumonia in Children (2019 edition). 3.PIBO has been diagnosed for at least 6 weeks; 4.To participate in the study voluntarily, the legal guardian of the child signs the informed consent, and the process of obtaining informed consent is in line with the rules of the Ethics Committee (when the child is capable of making a decision to consent to participate in the study, his/her consent should also be obtained; If the child has met the conditions for signing informed consent, the child needs to sign informed consent before continuing the study);
Exclusion criteria
Exclusion criteria: 1.Other chronic lung diseases that cause wheezing, including but not limited to bronchial asthma, primary ciliary dyskinesia, various congenital abnormalities of bronchopulmonary development, tuberculosis, diffuse panbronchiolitis, and cystic fibrosis; 2.A history of premature birth; 3.History of organ transplantation, including hematopoietic stem cell transplantation; 4.History of toxic gas inhalation; 5.Have any autoimmune disease; 6.Have used or are using macrolides for more than 2 weeks within 6 months before study start; 7.Allergy or previous intolerance to macrolides; 8.The patient had poor compliance and could not complete this clinical study; 9.The investigator did not consider it appropriate to participate in this clinical study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptom severity score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency and types of acute respiratory infections;Inflammatory factor levels;Pulmonary ventilation function;Systemic corticosteroid treatment course;Liver and kidney function;electrocardiogram data;Antibiotic treatment course;Vital signs;HRCT-based pulmonary severity scoring;6-minute walk test (6MWT); | — |
Countries
China
Contacts
Public ContactDehui Chen
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed